Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4231890 | 1.00 | TDP1 (0.51) | TDP1ATMALDH1A1MAPTLMNA | |
| SCHEMBL17786752 | 0.90 | ATM (0.62) | TDP1ATMALDH1A1MAPTLMNA | |
| SCHEMBL30317901 | 0.89 | TDP1 (0.50) | TDP1ATMALDH1A1MAPTLMNA | |
| SCHEMBL4233404 | 0.85 | HSPB1 (0.64) | TDP1ALDH1A1MAPTHSPB1MEN1 | |
| SCHEMBL30127752 | 0.82 | TDP1 (0.53) | TDP1ATMALDH1A1MAPTHSPB1 | |
| SCHEMBL16792668 | 0.82 | TDP1 (0.53) | TDP1ATMALDH1A1MAPTHSPB1 | |
| SCHEMBL2549018 | 0.81 | TDP1 (0.45) | TDP1ATMALDH1A1MAPTLMNA | |
| SCHEMBL5857081 | 0.81 | TDP1 (0.51) | TDP1ATMALDH1A1MAPTLMNA | |
| SCHEMBL863328 | 0.80 | NR4A1 (0.61) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL866003 | 0.79 | ALDH1A1 (0.62) | TDP1ALDH1A1MAPTLMNAHSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | TDP1 2128/4885ATM 4406/4885ALDH1A1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.